EARS

Altamira Therapeutics Ltd. [EARS] Stock Forecast

Q: What is Altamira Therapeutics Ltd. stock symbol ?

Altamira Therapeutics Ltd. is a CH stock, located in Zug of Zug and trading under the symbol EARS

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

EARS Stock Summary

Earnings have grown 378.41% per last year.

Earnings are expected to fall -100% next year

Does not have any significance market cap ($4.21M)

EARS has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

In the News

09:00 29 Nov 2023 EARS

Auris Medical Announces Launch of New Corporate Website

Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company's recently announced strategic repositioning.

03:58 29 Nov 2023 EARS

5 Reddit Penny Stocks to Watch That Are Moving Right Now

Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:40 29 Nov 2023 EARS

Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19

Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional preclinical data in a primary human nasal airway epithelium model from its Bentrio (AM-301) nasal spray for COVID-19. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.

09:00 29 Nov 2023 EARS

Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript describing these preclinical data is available on a preprint server at https://www.biorxiv.org/content/10.1101/2021.07.12.452021v1 and will undergo scientific peer-review for potential publication.

08:30 29 Nov 2023 EARS

Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany

Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries.

09:28 29 Nov 2023 EARS

EARS Stock Price Increases Over 14% Pre-Market

The stock price of Auris Medical Holding Ltd. (NASDAQ: EARS) increased by over 14% pre-market.

09:17 29 Nov 2023 EARS

Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs

Auris Medical Holding Ltd (NASDAQ: EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares, the assumption of certain selling shareholders' cash outlays, as well as a future share-based payment contingent on reaching a specific development milestone.

08:51 29 Nov 2023 EARS

EARS Stock Price: Over 9% Increase Pre-Market Explanation

The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by over 9% pre-market. This is why it happened.

08:30 29 Nov 2023 EARS

Auris Medical Holding to Present at LD Micro Invitational XI Conference

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.

08:30 29 Nov 2023 EARS

Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo.

EARS Financial details

Company Rating

Buy

Market Cap

4.21M

Income

9.65M

Revenue

1.45M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

31 Mar 2021

P/E

-2.05

Forward P/E

PEG

-0.24

P/S

P/B

P/C

P/FCF

Quick Ratio

Current Ratio

Debt / Equity

-1.9

LT Debt / Equity

-0.67

EPS (TTM)

-48.52

EPS next Y

EPS next Q

EPS this Y

10.93%

EPS next Y

EPS next 5Y

EPS last 5Y

-36.81%

Revenue last 5Y

-24.74%

Revenue Q/Q

-523.21%

EPS Q/Q

-52.17%

SMA20

-40%

SMA50

-50%

SMA100

Inst Own

35.89%

Inst Trans

0.76%

ROA

ROE

ROC

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

1.38M

Shs Float

Target Price

52W Range

3.0004-3.09

52W High

+1.5%

52W Low

+1.5%

RSI

Rel Volume

0.09

Avg Volume

1.89M

Volume

174.07K

Perf Week

8.36%

Perf Month

-42.87%

Perf Quarter

Perf Half Y

Beta

1.40479

Volatility

0.18%, 1.09%

Prev Close

23.28%

Price

3.045

Change

19.88%

EARS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	31.85	-0.39	0.58	0.1	0.34
Net income per share	-289.2	-45.6	-27.27	-26.26	-29.13
Operating cash flow per share	-332.87	-57.71	-16.11	-20.64	-9.53
Free cash flow per share	-380.44	-78.46	-23.81	-25.67	-11.89
Cash per share	135.67	9.52	37.44	1.49	0.02
Book value per share	91.81	41.5	55.77	19.18	-9.13
Tangible book value per share	2.88	-5.02	25.45	-2.43	-13.41
Share holders equity per share	91.81	41.5	55.77	19.18	-9.13
Interest debt per share	63.03	0.2	2.19	1.16	7.95
Market cap	7.13M	4.56M	13.89M	21.97M	4.08M
Enterprise value	3.17M	3.18M	3.16M	21.56M	10.4M
P/E ratio	-0.62	-0.69	-1.69	-1.26	-0.15
Price to sales ratio	5.63	-81.51	79.62	343.87	13.36
POCF ratio	-0.54	-0.54	-2.87	-1.61	-0.47
PFCF ratio	-0.47	-0.4	-1.94	-1.29	-0.38
P/B Ratio	1.95	0.76	0.83	1.73	-0.49
PTB ratio	1.95	0.76	0.83	1.73	-0.49
EV to sales	2.51	-56.79	18.09	337.48	34.02
Enterprise value over EBITDA	-0.29	-0.44	-0.6	-1.27	-0.4
EV to operating cash flow	-0.24	-0.38	-0.65	-1.58	-1.2
EV to free cash flow	-0.21	-0.28	-0.44	-1.27	-0.96
Earnings yield	-1.61	-1.45	-0.59	-0.79	-6.5
Free cash flow yield	-2.12	-2.5	-0.52	-0.77	-2.65
Debt to equity	0.39	0	0.03	0.05	-0.76
Debt to assets	0.15	0	0.03	0.03	1
Net debt to EBITDA	0.36	0.19	2.03	0.02	-0.24
Current ratio	1.33	1.04	3.83	0.77	0.14
Interest coverage	-10.24	-253.57	-39.09	-90.14	-28.66
Income quality	1.15	1.27	0.59	0.79	0.33
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	3.37	-70.25	14.87	76.64	11.52
Research and developement to revenue	5.28	-59.38	16.41	139.93	64.39
Intangibles to total assets	0.36	0.73	0.44	0.76	0.62
Capex to operating cash flow	0.14	0.36	0.48	0.24	0.25
Capex to revenue	-1.49	53.9	-13.27	-52.06	-7.01
Capex to depreciation	-26.01	-97.93	-115.55	-43.56	-18.02
Stock based compensation to revenue	0.02	-4.05	2.11	18.88	1.12
Graham number	772.93	206.33	184.98	106.45	77.35
ROIC	-2.19	-1.17	-0.3	-1.24	17.16
Return on tangible assets	-1.81	-2.7	-0.7	-3.84	-11.01
Graham Net	-15.94	-3.41K	-571.31	-6.08	-15.4
Working capital	1.5M	95.8K	8.59M	-1.1M	-11.11M
Tangible asset value	114.41K	-729.48K	7.65M	-1.61M	-12.21M
Net current asset value	-162.35K	-816.15K	7.59M	-2.37M	-12.85M
Invested capital	0.39	0	0.03	0.05	-0.76
Average receivables	280.83K	327.84K	208.08K	510.22K	851.05K
Average payables	1.52M	1.39M	850.35K	2.15M	4.16M
Average inventory	-79.94K	-494.29M	-673.33M	-178.67M	425.43K
Days sales outstanding	92.37	-2.19K	169.16	5.37K	910.68
Days payables outstanding	0	0	0	577.4	1.21K
Days of inventory on hand	0	0	0	136.71	2.94
Receivables turnover	3.95	-0.17	2.16	0.07	0.4
Payables turnover	0	0	0	0.63	0.3
Inventory turnover	0	0	0	2.67	124
ROE	-3.15	-1.1	-0.49	-1.37	3.19
Capex per share	-47.57	-20.75	-7.7	-5.02	-2.35

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2021-06-30	2021-12-31	2022-06-30	2022-12-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	0	0	0	0	0
Operating cash flow per share	0	0	0	0	0
Free cash flow per share	0	0	0	0	0
Cash per share	0	0	0	0	0
Book value per share	0	0	0	0	0
Tangible book value per share	0	0	0	0	0
Share holders equity per share	0	0	0	0	0
Interest debt per share	0	0	0	0	0
Market cap	0	0	0	0	0
Enterprise value	-8.47M	-408.46K	4.85M	6.32M	3.42M
P/E ratio	0	0	0	0	0
Price to sales ratio	0	0	0	0	0
POCF ratio	0	0	0	0	0
PFCF ratio	0	0	0	0	0
P/B Ratio	0	0	0	0	0
PTB ratio	0	0	0	0	0
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0	0	0	0	0
EV to operating cash flow	0	0.08	0	0	0
EV to free cash flow	0	0.12	0	0	0
Earnings yield	0	0	0	0	0
Free cash flow yield	0	0	0	0	0
Debt to equity	0	0.05	0.68	-0.76	-1.9
Debt to assets	0	0.03	0.28	1	0.56
Net debt to EBITDA	0	0	0	0	0
Current ratio	2.98	0.77	0.2	0.14	0.32
Interest coverage	0	0	0	0	0
Income quality	0	-0.56	0	0	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.61	0.76	0.86	0.62	0.63
Capex to operating cash flow	0	-0.35	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	-37.99	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	0	0	0	0
ROIC	0	0	0	0	0
Return on tangible assets	0	0	0	0	0
Graham Net	0	0	0	0	0
Working capital	6.08M	-1.1M	-7.86M	-11.11M	-3.64M
Tangible asset value	5.54M	-1.61M	-8.18M	-12.21M	-5.72M
Net current asset value	5.5M	-2.37M	-8.88M	-12.85M	-6.3M
Invested capital	0	0.05	0.68	-0.76	-1.9
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0	0	0	0	0
Capex per share	0	0	0	0	0

EARS Frequently Asked Questions

What is Altamira Therapeutics Ltd. stock symbol ?

Altamira Therapeutics Ltd. is a CH stock , located in Zug of Zug and trading under the symbol EARS

What is Altamira Therapeutics Ltd. stock quote today ?

Altamira Therapeutics Ltd. stock price is $3.045 today.

Is Altamira Therapeutics Ltd. stock public?

Yes, Altamira Therapeutics Ltd. is a publicly traded company.

Something similar

Top by Market Cap

LLY

AAPL

ABEA.DE

Company Profile

Volume Average 1.89M
Market Capitalization 4.21M
Employee 8
CEO Dr. Thomas Meyer
Headquarters Zug,ZUG,CH
IPO Date 2014-08-06
Website http://www.aurismedical.com

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.